Francisco Esteva: ADCs are making waves in the fight against advanced HER2+ breast cancer
“Antibody-drug conjugates are making waves in the fight against advanced HER2-positive breast cancer.
I recently reviewed the latest data on Trastuzumab Duocarmazine, T-Duo. In a phase III trial, T-Duo was compared against the physician’s choice of treatment in patients with progressive metastatic HER2+ breast cancer.
The trial included 437 patients and showed that T-Duo extended progression-free survival to a median of 7.0 months, compared to 4.9 months with the physician’s choice. While the difference in overall survival wasn’t statistically significant, T-Duo treated patients had a better progression-free survival rate.
The treatment does come with some safety concerns, particularly ocular toxicity, but adverse events were generally manageable.
These findings highlight the potential of this experimental treatment, T-Duo in providing more options for patients facing advanced HER2+ breast cancer when other therapies have failed.
It makes me wonder: how might these findings shape future treatment protocols? What will be required to get new HER2-targeted antibody-drug conjugates approved by regulatory agencies? Let’s discuss and share our thoughts.”
Authors: Nicholas Turner, Cristina Saura, Philippe Aftimos, Santiago Escrivá-de-Romaní, Joyce O’Shaughnessy et al.
More posts featuring Francisco Esteva.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023